ProKidney Stock (NASDAQ:PROK)
Previous Close
$2.00
52W Range
$0.54 - $7.13
50D Avg
$2.05
200D Avg
$2.45
Market Cap
$561.66M
Avg Vol (3M)
$886.80K
Beta
1.86
Div Yield
-
PROK Company Profile
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.